Literature DB >> 21789338

[German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids].

K-J Langen1, P Bartenstein, H Boecker, P Brust, H H Coenen, A Drzezga, F Grünwald, B J Krause, T Kuwert, O Sabri, K Tatsch, W A Weber, M Schreckenberger.   

Abstract

For the primary diagnosis of brain tumours, morphological imaging by means of magnetic resonance imaging (MRI) is the current method of choice. The complementary use of functional imaging by positron emitting tomography (PET) and single photon emitting computerized tomography (SPECT) with labelled amino acids can provide significant information on some clinically relevant questions, which are beyond the capacity of MRI. These diagnostic issues affect in particular the improvement of biopsy targeting and tumour delineation for surgery and radiotherapy planning. In addition, amino acid labelled PET and SPECT tracers are helpful for the differentiation between tumour recurrence and non-specific post-therapeutic tissue changes, in predicting prognosis of low grade gliomas, and for metabolic monitoring of treatment response. The application of dynamic PET examination protocols for the assessment of amino acid kinetics has been shown to enable an improved non-invasive tumour grading. The purpose of this guideline is to provide practical assistance for indication, examination procedure and image analysis of brain PET/SPECT with labelled amino acids in order to allow for a high quality standard of the method. After a short introduction on pathobiochemistry and radiopharmacy of amino acid labelled tracers, concrete and detailed information is given on the several indications, patient preparation and examination protocols as well as on data reconstruction, visual and quantitative image analysis and interpretation. In addition, possible pitfalls are described, and the relevant original publications are listed for further information.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21789338     DOI: 10.3413/nuk-2011041

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  41 in total

1.  Multimodal imaging utilising integrated MR-PET for human brain tumour assessment.

Authors:  Irene Neuner; Joachim B Kaffanke; Karl-Josef Langen; Elena Rota Kops; Lutz Tellmann; Gabriele Stoffels; Christoph Weirich; Christian Filss; Jürgen Scheins; Hans Herzog; N Jon Shah
Journal:  Eur Radiol       Date:  2012-07-11       Impact factor: 5.315

2.  Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.

Authors:  Nathalie L Albert; Isabel Winkelmann; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Erik Mille; Andrei Todica; Matthias Brendel; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-15       Impact factor: 9.236

3.  Reply to "[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.

Authors:  Karl-Josef Langen; Norbert Galldiks
Journal:  Neuro Oncol       Date:  2013-06-07       Impact factor: 12.300

4.  The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.

Authors:  Norbert Galldiks; Gabriele Stoffels; Christian Filss; Marion Rapp; Tobias Blau; Caroline Tscherpel; Garry Ceccon; Veronika Dunkl; Martin Weinzierl; Michael Stoffel; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

5.  Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas.

Authors:  Philipp Lohmann; Hans Herzog; Elena Rota Kops; Gabriele Stoffels; Natalie Judov; Christian Filss; Norbert Galldiks; Lutz Tellmann; Carolin Weiss; Michael Sabel; Heinz Hubert Coenen; Nadim Jon Shah; Karl-Josef Langen
Journal:  Eur Radiol       Date:  2015-03-27       Impact factor: 5.315

6.  Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-L-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake.

Authors:  Carina Stegmayr; Gabriele Stoffels; Elena Rota Kops; Philipp Lohmann; Norbert Galldiks; Nadim J Shah; Bernd Neumaier; Karl-Josef Langen
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

7.  Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma.

Authors:  Olivia Kertels; Almuth F Kessler; Milena I Mihovilovic; Antje Stolzenburg; Thomas Linsenmann; Samuel Samnick; Stephanie Brändlein; Camelia Maria Monoranu; Ralf-Ingo Ernestus; Andreas K Buck; Mario Löhr; Constantin Lapa
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

8.  Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.

Authors:  Garry Ceccon; Philipp Lohmann; Gabriele Stoffels; Natalie Judov; Christian P Filss; Marion Rapp; Elena Bauer; Christina Hamisch; Maximilian I Ruge; Martin Kocher; Klaus Kuchelmeister; Bernd Sellhaus; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

9.  Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans.

Authors:  Philipp Lohmann; Gabriele Stoffels; Garry Ceccon; Marion Rapp; Michael Sabel; Christian P Filss; Marcel A Kamp; Carina Stegmayr; Bernd Neumaier; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur Radiol       Date:  2016-11-16       Impact factor: 5.315

10.  Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results.

Authors:  Jan F Cornelius; Gabriele Stoffels; Christian Filß; Norbert Galldiks; Philipp Slotty; Marcel Kamp; Mustafa el Khatib; Daniel Hänggi; Michael Sabel; Jörg Felsberg; Hans Jakob Steiger; Heinz H Coenen; Nadim J Shah; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.